Hypera S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
July 27, 2023 at 06:17 pm EDT
Share
Hypera S.A. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was BRL 2,231.08 million compared to BRL 1,895.64 million a year ago. Net income was BRL 503.91 million compared to BRL 455.93 million a year ago. Basic earnings per share from continuing operations was BRL 0.8 compared to BRL 0.72 a year ago. Basic earnings per share was BRL 0.79 compared to BRL 0.72 a year ago.
For the six months, sales was BRL 3,929.27 million compared to BRL 3,389.19 million a year ago. Net income was BRL 843.16 million compared to BRL 802.82 million a year ago. Basic earnings per share from continuing operations was BRL 1.33 compared to BRL 1.27 a year ago. Basic earnings per share was BRL 1.33 compared to BRL 1.27 a year ago.
Hypera (formerly Hypermarcas) is the Brazilian leader in the manufacture and marketing of pharmaceutical products. The products are sold primarily under the Addera D3, Adocyl, AdultMax, Alivium, Apracur, Atroveran, Benegrip, Bigfral, Biotonico Fontoura, Coristina, Cremer, Doril, Engov, Epocler, Lisador and Neo Quimica. The activity is organized around 3 families of products :
- OTC medicines;
- prescription medicines;
- branded generic medicines.
HYPERA S.A. 
